Evidence map›Paper›PMID 33573996›Full record

ReviewThe American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry2021

Cannabinoids for Agitation in Alzheimer's Disease.

John D Outen, M Haroon Burhanullah, Ryan Vandrey, Halima Amjad, David G Harper, Regan E Patrick, Rose L May, Marc E Agronin, Brent P Forester, Paul B Rosenberg

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review: Cannabinoids as Medicinals.Current addiction reports · 2022
    Review
  15. Commentary on "Cannabinoids for Agitation in Alzheimer's Disease".The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2021
    Article
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

John D OutenDepartment of Psychiatry & Behavioral Sciences (JDO, HB, PBR), Johns Hopkins University School of Medicine, Baltimore, MD.
M Haroon BurhanullahDepartment of Psychiatry & Behavioral Sciences (JDO, HB, PBR), Johns Hopkins University School of Medicine, Baltimore, MD.
Ryan VandreyBehavioral Pharmacology Research (RV), Johns Hopkins University School of Medicine, Baltimore, MD.
Halima AmjadGeriatric Medicine and Gerontology (HA), Johns Hopkins University School of Medicine, Baltimore, MD.
David G HarperDivision of Geriatric Psychiatry (DGH, REP, RLM, BPF), McLean Hospital, Belmont, MA; Department of Psychiatry (DGH, REP, BPF), Harvard Medical School, Boston, MA.
Regan E PatrickDivision of Geriatric Psychiatry (DGH, REP, RLM, BPF), McLean Hospital, Belmont, MA; Department of Psychiatry (DGH, REP, BPF), Harvard Medical School, Boston, MA.
Rose L MayDivision of Geriatric Psychiatry (DGH, REP, RLM, BPF), McLean Hospital, Belmont, MA.
Marc E AgroninDepartment of Mental Health and Clinical Research (MEA), Miami Jewish Health, Miami, FL.
Brent P ForesterDivision of Geriatric Psychiatry (DGH, REP, RLM, BPF), McLean Hospital, Belmont, MA; Department of Psychiatry (DGH, REP, BPF), Harvard Medical School, Boston, MA.
Paul B RosenbergDepartment of Psychiatry & Behavioral Sciences (JDO, HB, PBR), Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address: prosenb9@jhmi.edu.
Johns Hopkins University · USMcLean Hospital · USBehavioral Pharma (United States) · USHarvard University · USJohns Hopkins Medicine · US

Funding

Research Education ComponentP30AG066507 · NIA · JOHNS HOPKINS UNIVERSITY · PI Corinne Pettigrew · 2020 to 2026
$29.3M
Pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer's disease (AD)R01AG050515 · NIA · JOHNS HOPKINS UNIVERSITY · PI FORESTER, BRENT PETER, ROSENBERG, PAUL B · 2016 to 2021
$5.5M
NIA NIH HHS P30 AG066507NIA NIH HHS R01 AG050515
6 · The paper itself

Abstract

Agitation is a common neuropsychiatric symptom of Alzheimer's disease (AD) that greatly impacts quality of life and amplifies caregiver burden. Agitation in AD may be associated with volume loss in the anterior cingulate cortex, posterior cingulate cortex, insula, amygdala, and frontal cortex, as well as with degeneration of monoaminergic neurotransmission, disrupted circadian rhythms, and frailty. Current pharmacologic options have troubling safety concerns and only modest efficacy. There is increasing interest in cannabinoids as promising agents due to preclinical and early clinical research that suggest cannabinoids can elicit anxiolytic, antidepressant, and/or anti-inflammatory effects. Cannabinoids may relieve agitation by regulating neurotransmitters, improving comorbidities and circadian rhythms, and increasing cerebral circulation. Here we discuss the possible contributory mechanisms for agitation in AD and the therapeutic relevance of cannabinoids, including CBD and THC.

Indexed as

Alzheimer DiseaseCannabinoidsFrontal LobeHumansPsychomotor AgitationQuality of LifeCannabinoidsaggressionagitationAlzheimer's diseasecannabinoidsCBDdementiamechanismsneuropsychiatric symptomsTHC

Identifiers

PMID33573996
PMCPMC8313629
OpenAlexW3125359144

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.